Ono Pharmaceutical Co., Ltd. (小野薬品工業株式会社, Ono Yakuhin Kōgyō Kabushiki-gaisha) is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono (Japanese: 小野市兵衛) started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. (Japanese: 小野薬品工業株式会社) in 1948.Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.Nivolumab, the cancer drug based on the research of Prof.Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb..
OBJECTIVE:We investigated the factors associated with treatment discontinuation and safety of abatacept treatment up to 5 years as the first-line biologic in Japanese patients with rheumatoid arthritis (RA) of moderate disease activity (MDA). METHODS:We analyzed 5-year data from the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study (UMIN000021263). We examined the factors associated with treatment discontinuation, overall and age-stratified safety, and effectiveness. RESULTS:Among 279 analyzed patients, the cumulative incidence (95% CI) of discontinuation was 0.210 (0.158-0.262) for insufficient effectiveness and 0.266 (0.208-0.323) for adverse events (AEs). Older age (subdistribution hazard ratio [95% CI] 0.970 [0.946-0.995]; P = .018) and anti-citrullinated peptide antibody-positive status (0.284 [0.140-0.575]; P < .001) were associated with lower risk of discontinuation due to insufficient effectiveness. Presence of comorbidities was associated with greater risk of discontinuation due to AEs. The frequencies of AEs and adverse drug reactions remained stable or decreased over time. The safety was consistent with prior analyses of ORIGAMI and comparable among three age groups (<65, ≥65 to <75, and ≥75 years). CONCLUSIONS:Five-year results of the ORIGAMI study provide further evidence supporting the factors associated with long-term treatment continuation and safety of subcutaneous abatacept in patients with RA of MDA.
The clinical practice guidelines for chronic kidney disease (CKD) in 2018 and the launch of the first therapeutic agent in 2021 are expected to have improved CKD management in Japan. However, the reality of CKD diagnosis in this environment is poorly understood. Here, we conducted a retrospective observational study. We investigated the changes in CKD diagnosis rates, the characteristics of diagnosed cases, and the prognostic impact of the timing of diagnosis by using a database of administrative claims and medical checkups from 2014 to 2023 (DeSC Healthcare Inc.™) for patients with a potential risk of CKD (eGFR <60 mL/min/1.73 m2 and/or urine protein qualitative test result of ≥1+). We extracted 287,999 patients who newly met the diagnostic criteria for CKD at a medical checkup. The rate of new CKD diagnosis remained 3
A BRAF inhibitor, encorafenib, combined with a MEK inhibitor, binimetinib, was approved in Japan in early 2019 for the treatment of BRAF V600-mutant, unresectable malignant melanoma based on results of the global phase III trial, COLUMBUS, conducted in various countries including Japan. This post-marketing surveillance (PMS) assessed the combination in real-world clinical practice in Japan. We performed a prospective, multicentre, 12-month PMS of the safety and effectiveness of encorafenib plus binimetinib for radically unresectable, BRAF-mutant malignant melanoma in Japan. Among 174 survey forms collected from 85 centres between February 2019 and August 2020, 172 were included for safety and effectiveness analysis. Patients (male [52.3
4501 Background: In the JAVELIN Bladder 100 phase 3 trial, avelumab 1L maintenance + best supportive care (BSC) significantly prolonged overall survival (OS) and progression-free survival (PFS) vs BSC alone in pts with aUC without progression following 1L platinum-based chemotherapy (PBC). The JAVELIN Bladder Medley phase 2 trial is investigating the combination of avelumab with other antitumor agents in this pt population to assess efficacy and safety vs avelumab maintenance monotherapy. SG is a Trop-2–directed antibody and topoisomerase inhibitor drug conjugate being investigated in solid tumors. Here we report an interim analysis of avelumab + SG vs avelumab monotherapy. Methods: Eligible pts had unresectable locally advanced or metastatic UC, ECOG performance status (PS) 0-1, and no disease progression after 4-6 cycles of 1L PBC. Pts were randomized 2:1 to avelumab + SG or avelumab monotherapy, stratified by presence of visceral metastases at start of 1L PBC. Primary endpoints were investigator-assessed PFS and safety; OS was a secondary endpoint. For PFS and OS analyses, data in the avelumab monotherapy arm were extended per protocol using propensity score-weighted JAVELIN Bladder 100 data. Results: At data cutoff (Sep 16, 2024), 38 of 74 pts (51.4%) in the avelumab + SG arm and 10 of 37 pts (27.0%) in the avelumab monotherapy arm were still receiving study treatment. In the avelumab + SG and avelumab monotherapy arms, respectively, median age was 70 and 67 years, 50.0% and 51.4% had visceral metastases at start of 1L PBC, and a lower proportion of pts in the avelumab + SG arm had ECOG PS of 1 (31.1% vs 54.1%). Median PFS was 11.17 months (95% CI, 7.43-not estimable [NE]) with avelumab + SG vs 3.75 months (95% CI, 3.32-6.77) with avelumab monotherapy (hazard ratio [HR], 0.49 [95% CI, 0.31-0.76]). OS data were immature at cutoff; median OS was not reached (95% CI, 15.51-NE) in the avelumab + SG arm vs 23.75 months (95% CI, 18.79-30.82) in the avelumab monotherapy arm (HR, 0.79 [95% CI, 0.42-1.50]). In the avelumab + SG and avelumab monotherapy arms, respectively, treatment-related adverse events (TRAEs) of any grade occurred in 71 (97.3%) vs 23 pts (63.9%), and were grade ≥3 in 51 (69.9%) vs 0 pts. TRAEs led to discontinuation of both avelumab + SG in 4.1% (SG only in 12.3%) vs avelumab monotherapy in 2.8%. One pt in the avelumab + SG arm had a SG-related AE that led to death (acute subarachnoid hemorrhage in the setting of sepsis and pancytopenia). Conclusions: In pts with aUC without progression after 1L PBC, avelumab + SG as maintenance treatment improved PFS vs avelumab monotherapy. TRAEs were more frequent in the combination arm and were consistent with the known safety profile of SG and avelumab. Further investigation of avelumab in combination with anti–Trop-2 antibody-drug conjugates in aUC is warranted. Clinical trial information: NCT05327530 .
Mature T and NK-cell neoplasms are of mature T-cell or NK-cell origin and comprise approximately 10% to 15% of non-Hodgkin’s lymphomas (NHLs) all over the world. While new therapies with novel mechanisms of action have become available, their therapeutic outcomes are limited and most subtypes of the neoplasms have a poor prognosis. Therefore, identification of new therapeutic approaches is still an unmet medical need.Programmed cell death 1 (PD-1) is an inhibitory receptor expressed and increased on normal activated T and B cells that promotes T-cell apoptosis, anergy and functional exhaustion. PD-1 is also expressed on multiple different cancer types including major T-cell lymphomas/leukemias: Angioimmunoblastic T-cell lymphoma (AITL); Nodal T-cell lymphoma with T follicular helper (Tfh) phenotype; Follicular T-cell lymphoma; Peripheral T-cell lymphoma (PTCL) not otherwise specified (PTCL-NOS); Cutaneous T-cell lymphoma (CTCL) mycosis fungoides (CTCL-MF); CTCL Sézary syndrome (CTCL-SS), and; Adult T-cell leukemia/lymphoma (ATLL). Thus, PD-1 is a novel potential therapeutic target for T-cell lymphomas/leukemias.ONO-4685 is a first-in-class bispecific TCE antibody that binds to human PD-1 and CD3 to engage T-cells with PD-1 expressing tumor cells. TCEs have recently shown clinical anticancer success with some hematologic malignancies and solid tumor types.Here we performed preclinical studies to evaluate the therapeutic value of ONO-4685 to treat PD-1 expressing T-cell malignancies.To evaluate the effect of ONO-4685 on the cytolytic activity of T-cells, peripheral blood mononuclear cells (PBMCs) from healthy donors as well as PD-1 expressing T cell lymphoma/leukemia cell lines (ILT-Mat, HPB-ALL, and SUP-T1) were co-cultured in the presence of ONO-4685. ONO-4685 induced potent cytolytic cell killing of the cell lines. To assess the effect of ONO-4685 on T-cells, the intracellular expression of T-cell granzyme B was evaluated in in vitro cytotoxicity assay. ONO-4685 induced granzyme B expression in CD4+ and CD8+ T cells in the presence of PD-1-expressing target cells (ILT-Mat). Moreover, ONO-4685-mediated cytotoxicity on PD-1 expressing target cells was observed in the PBMCs from ATLL patients. In vivo anti-tumor activity of ONO-4685 was evaluated in PBMC-humanized mice xenograft models using PD-1 expressing human T cell lymphoma/leukemia cell lines (SUP-T1 and TL-Mor). ONO-4685 treatment showed suppressive effects on tumor growth in a dose-dependent manner.Taken together, these preclinical data support the clinical development of ONO-4685 as a novel TCE targeting PD-1 expressing hematologic malignancies. A Phase I clinical study in the USA is ongoing to evaluate the safety and tolerability of ONO-4685 in relapsed or refractory patients with PTCL and CTCL (NCT05079282). Naho Tateshita, Noriki Watanabe, Takuya Shimbo, Akihiro Morimoto, Kazuhiko Takeda, Tatsuya Tanihiro. ONO-4685: A novel PD-1/CD3 bispecific T-cell engager (TCE) for the treatment of T-cell malignancies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7324.